Hemogenyx Pharmaceuticals Plc

570.00pAs of Sun 8 Nov 2026, 12:00 UTC
LSE:HEMOHealthcare
Ctry United Kingdom
PE (Fwd) •••
TSR 9Y CAGR (6.55%)
Div yield —
ROE (607.36%)
Biotechnology
Beta (5Y) 1.48
PE TTM —
TSR TTM (34.03%)
Mkt cap £38.76M
ROIC (187.95%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
619p
8.52%
(85.74%)
Hold 6|5|2|6|7
4Q25
1Q26
2Q26
3Q26
Earnings per share£
12.84
13.17
13.14
13.10
16.63%
19.89%
7.72%
9.16%
Revenue£M
2.466
2.396
2.370
2.417
(2.90%)
(3.33%)
(6.41%)
(2.32%)
Peers (US$52.15M)
Cap (US$)
PE
62.15M
—
52.12M
—
Capital
TTM
5Y
10Y
Leveragex
0.965
0.096
0.071
EBIT/Intx
0.804
0.209
0.206
Own earn%
(35.43)
94.27
47.38
Sh yield%
34.61
51.68
47.81
Owners
Insiders/Inst%
1.65
27.79
Short interest%
5.45
SBC / revenue%
3.13
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
7–12
$1 testx
0.0
Incr. ROIC%
1